首页> 外国专利> HYDROXYALKYLSTRACH (HAS)-POLYPEPTIDE-CONJUGATE(HAS-POLYPEPTIDE), A METHOD FOR ITS PRODUCTION AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THERATING ANEMIC DISORDERS

HYDROXYALKYLSTRACH (HAS)-POLYPEPTIDE-CONJUGATE(HAS-POLYPEPTIDE), A METHOD FOR ITS PRODUCTION AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THERATING ANEMIC DISORDERS

机译:羟烷基-多肽-共轭物(HAS-多肽),其生产方法及其在治疗贫血的药物中的用途

摘要

Preparation of hydroxyalkyl starch derivatives involves reaction of hydroxyalkyl starch at its reducing end with amino compound. The reducing end is not oxidized prior to the reaction. Preparation of hydroxyalkyl starch derivatives involves reaction of hydroxyalkyl starch of formula (I) at its reducing end with amino compound of formula R a-NH-R b (II). [Image] R 1-R 3H, linear or branched hydroxyalkyl; R aat least one functional group X capable of reacting with at least one other compound prior to or after the reaction; R ba functional group X or W; W : -NH-, -NH-C(=G)-, -NH-C(=G)-G-, -NH-S(O) 2- or -NH-C(=G)-NH-; X : -SH, -NH 2, -O-NH 2, -NH-O-alkyl, -C(=G)-NH-NH 2, -G-C(=G)-NH-NH 2, -NH-C(=G)-NH-NH 2 or -S(O) 2-NH-NH 2; and G : O or S. An independent claim is included for a pharmaceutical composition comprising the hydroxyalkyl starch derivative (where the reaction product of (I) with (II) is reacted via the functional group X in (II) with the further compound (III) or (II) is reacted via the functional group X with (III) prior to the reaction with (I), and the reaction product of (I) and (II) with the crosslinking compound is reacted with a polypeptide). ACTIVITY : Antianemic. Hydroxyethyl starch-erythropoietin (HES-EPO) was tested by the EPO-bioassay in normocythaemic mouse system and showed specific activity of 344000 U/mg, which was 3 fold higher than international BRP-erythropoietin reference standard preparation. MECHANISM OF ACTION : None given.
机译:羟烷基淀粉衍生物的制备涉及羟烷基淀粉在其还原端与氨基化合物的反应。还原端在反应之前不被氧化。羟烷基淀粉衍生物的制备涉及式(I)的羟烷基淀粉在其还原端与式R a-NH-R b(II)的氨基化合物反应。 [图像] R 1-R 3H,直链或支链羟烷基; R a在反应之前或之后能够与至少一种其他化合物反应的至少一个官能团X; R ba官能团X或W; W:-NH-,-NH-C(= G)-,-NH-C(= G)-G-,-NH-S(O)2-或-NH-C(= G)-NH-; X:-SH,-NH 2 --O-NH 2 --NH-O-烷基,-C(= G)-NH-NH 2 --GC(= G)-NH-NH 2 --NH-C (= G)-NH-NH 2或-S(O)2-NH-NH 2;对于包含羟烷基淀粉衍生物的药物组合物包括独立的权利要求(其中(I)与(II)的反应产物通过(II)中的官能团X与另外的化合物(在与(I)反应之前,使III)或(II)经由官能团X与(III)反应,并使(I)和(II)与交联化合物的反应产物与多肽反应)。活动:抗贫血。羟乙基淀粉促红细胞生成素(HES-EPO)在正血红细胞小鼠系统中通过EPO-生物测定法进行测试,显示比活性为344000 U / mg,比国际BRP-促红细胞生成素参考标准制剂高3倍。作用机理:未给出。

著录项

  • 公开/公告号IL200150A

    专利类型

  • 公开/公告日2011-07-31

    原文格式PDF

  • 申请/专利权人 FRESENIUS KABI DEUTSCHLAND GMBH;

    申请/专利号IL200150

  • 发明设计人

    申请日2009-07-30

  • 分类号C07Knull/null;

  • 国家 IL

  • 入库时间 2022-08-21 18:06:19

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号